{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:30:23Z","timestamp":1787729423571,"version":"build-2784847793"},"reference-count":30,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3,1]]},"DOI":"10.1210\/jc.2013-3081","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T10:06:36Z","timestamp":1389693996000},"page":"891-897","source":"Crossref","is-referenced-by-count":68,"title":["Effects of Denosumab Treatment and Discontinuation on Human Growth Plates"],"prefix":"10.1210","volume":"99","author":[{"given":"Howard D.","family":"Wang","sequence":"first","affiliation":[{"name":"Skeletal Clinical Studies Unit (H.D.W., J.Y.T., R.I.G., M.T.C.),Bethesda, Maryland 20892"},{"name":"University of Maryland School of Medicine (H.D.W.), Baltimore, Maryland 21201"},{"name":"Department of Plastic and Reconstructive Surgery (H.D.W.), Johns Hopkins Hospital, Baltimore, Maryland 21231"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Boyce","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes (A.M.B.), Washington, DC 20010"},{"name":"Bone Health Program (A.M.B.), Division of Orthopaedics and Sports Medicine, Children's National Medical Center, Washington, DC 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Y.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit (H.D.W., J.Y.T., R.I.G., M.T.C.),Bethesda, Maryland 20892"},{"name":"Tufts University School of Dental Medicine (J.Y.T.), Boston, Massachusetts 02111"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel I.","family":"Gafni","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit (H.D.W., J.Y.T., R.I.G., M.T.C.),Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Farley","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems (F.A.F., J.Z.K.-V.), University of Michigan, Ann Arbor, Michigan 48109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine Z.","family":"Kasa-Vubu","sequence":"additional","affiliation":[{"name":"University of Michigan Health Systems (F.A.F., J.Z.K.-V.), University of Michigan, Ann Arbor, Michigan 48109"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo A.","family":"Molinolo","sequence":"additional","affiliation":[{"name":"Craniofacial and Skeletal Diseases Branch, and Oral and Pharyngeal Cancer Branch (A.A.M.), National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Collins","sequence":"additional","affiliation":[{"name":"Skeletal Clinical Studies Unit (H.D.W., J.Y.T., R.I.G., M.T.C.),Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113331876900_B1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019041113331876900_B2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113331876900_B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041113331876900_B4","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113331876900_B5","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B6","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"key\n\t\t\t\t2019041113331876900_B7","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1056\/NEJMc1206193","article-title":"Denosumab for post-transplantation hypercalcemia in osteopetrosis","volume":"367","author":"Shroff","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113331876900_B8","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1200\/JCO.2012.46.4255","article-title":"Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl","volume":"31","author":"Karras","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113331876900_B9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113331876900_B12","first-page":"929","article-title":"Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome","volume":"15","author":"Matarazzo","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113331876900_B13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jcem-61-5-952","article-title":"Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis","volume":"61","author":"Hoekman","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113331876900_B14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t2019041113331876900_B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113331876900_B16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041113331876900_B17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1349-7006.2008.00803.x","article-title":"Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases","volume":"99","author":"Yonemori","year":"2008","journal-title":"Cancer Sci"},{"key":"key\n\t\t\t\t2019041113331876900_B18","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1148\/radiology.184.1.1609087","article-title":"Epi- and metaphyseal changes in children caused by administration of bisphosphonates","volume":"184","author":"van Persijn van Meerten","year":"1992","journal-title":"Radiology"},{"key":"key\n\t\t\t\t2019041113331876900_B20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","article-title":"Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta","volume":"21","author":"Land","year":"2006","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","article-title":"Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta","volume":"40","author":"Rauch","year":"2007","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113331876900_B23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113331876900_B24","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1359\/jbmr.080511","article-title":"Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases","volume":"23","author":"Whyte","year":"2008","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019041113331876900_B26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1359\/jbmr.081113","article-title":"Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing","volume":"24","author":"Gerstenfeld","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B27","first-page":"MO0405","article-title":"Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the FREEDOM trial","volume":"25","author":"Adami","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113331876900_B28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113331876900_B29","article-title":"Enhanced pre-postnatal toxicity study of AMG 162 administered by SC injection to pregnant cynomolgus monkeys with up to 6-months postnatal evaluation","author":"Bussiere"},{"key":"key\n\t\t\t\t2019041113331876900_B30","unstructured":"Bussiere JL . A 6\/12-month toxicity study of denosumab in cynomolgus monkeys. J Bone Miner Res. 2012;27(suppl 1). http:\/\/wwwasbmrorg\/meetings\/annualmeeting\/abstractdetailaspx?aid=cac1502d-a2de-4466-b0c2-7b8c61685eee. Accessed June 29, 2013."}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/3\/891\/11157973\/jcem0891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T13:24:42Z","timestamp":1565097882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/3\/891\/2537617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-3081","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}